Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study of the Safety, Tolerability, Feasibility and Efficacy of Anti-PD-1 or Anti-PD-L1 in Combination With a Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)

Next Previous
Search
Trial Profile

A Pilot Study of the Safety, Tolerability, Feasibility and Efficacy of Anti-PD-1 or Anti-PD-L1 in Combination With a Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EVX 01 (Primary) ; EVX 01 (Primary) ; Nivolumab; Pembrolizumab
  • Indications Bladder cancer; Carcinoma; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Acronyms NeoPepVac

Most Recent Events

  • 15 Jan 2025 According to a Evaxion media release, the trial remains on track for completion and data readout is expected in the second half of 2025.
  • 14 Aug 2024 According to a Evaxion media release, company is on track for Phase 2 one-year clinical data readout at the ESMO Congress 2024 in September (Q3 2024).
  • 17 Jun 2024 Results published in the Media Release

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top